Arterial Occlusive Diseases

4
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

C
CordisFL - Miami Lakes
3 programs
3
Smart StentPhase 41 trial
stentPhase 41 trial
stentPhase 41 trial
Active Trials
NCT00235131Completed200Est. May 2009
NCT00232843Completed150Est. May 2009
NCT00289055Terminated10Est. Jun 2008
Grifols
GrifolsNEW YORK, NY
1 program
1
PlasminPhase 11 trial
Active Trials
NCT00418483CompletedEst. Apr 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Cordisstent
CordisSmart Stent
Cordisstent
GrifolsPlasmin

Clinical Trials (4)

Total enrollment: 360 patients across 4 trials

NCT00289055Cordisstent

The Study to Compare the Treatment of Angioplasty and Stents in SFA Occlusions.

Start: Nov 2005Est. completion: Jun 200810 patients
Phase 4Terminated
NCT00235131CordisSmart Stent

The Study to Compare the Cordis SMART™ Stent System With the Bard® Luminexx™ Stent

Start: May 2005Est. completion: May 2009200 patients
Phase 4Completed
NCT00232843Cordisstent

The Study to Treat Superficial Femoral Artery Occlusions.

Start: Mar 2005Est. completion: May 2009150 patients
Phase 4Completed
NCT00418483GrifolsPlasmin

A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion

Start: Mar 2007Est. completion: Apr 2010
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space